ChemLifeIntelCHEMICAL & LIFE SCIENCES INTELLIGENCE
Access
REGULATORY INTELLIGENCEWarning LetterNotable

FDA Recall: Grace & Fire's Ultra Violette SPF 50 Sunscreen Exhibits Critical Efficacy Inconsistency

CM
Catherine MorrowView Profile →
Senior Regulatory Intelligence Analyst
EXECUTIVE SUMMARY

Grace & Fire PTY LTD has initiated a Class II recall for 44,497 tubes of its Ultra Violette Mini SPF Mates kit, including Velvet Screen SPF 50 and Supreme Sunscreen SPF 50, due to inconsistent SPF results ranging from 4 to 64. This significant quality failure, distributed nationwide in the USA, demands immediate attention from procurement and regulatory teams to reassess supplier quality and mitigate brand risk.

FDA Identifies Critical SPF Inconsistency in Ultra Violette Sunscreen Recall

Grace & Fire PTY LTD, based in Cremorne, Australia, has initiated a Class II voluntary recall, D-0641-2025, for 44,497 tubes of its Ultra Violette Mini SPF Mates kit. This kit includes the Velvet Screen SPF 50 Blurring Mineral SkinScreen, containing Zinc Oxide 22.75%, and the Supreme Sunscreen SPF 50. The recall, initiated on August 22, 2025, stems from critical quality control failures, specifically inconsistent SPF results. Testing revealed a dangerous variability, with SPF values ranging from as low as 4 to as high as 64, significantly deviating from the labeled SPF 50 claim. These affected products, identified by Lot #s A2453 (exp 11/30/2026) and A2454 (exp 12/31/2026), were distributed nationwide in the USA by Grace & Fire USA Inc. This wide distribution pattern means a substantial number of consumers are at risk of either inadequate sun protection or exposure to potentially higher concentrations of active ingredients than intended. For procurement directors and regulatory affairs heads, this event underscores the paramount importance of stringent quality assurance throughout the supply chain, particularly for over-the-counter (OTC) drug products where efficacy claims directly impact public health and regulatory compliance. The failure to consistently deliver the stated SPF 50 represents a fundamental breakdown in manufacturing process control and product quality, posing significant commercial and reputational risks.

Commercial Repercussions of Subpotent/Superpotent Sunscreen Products

The discovery of such a broad range of SPF values – from SPF 4 to SPF 64 – within a product labeled SPF 50 carries severe commercial repercussions for Grace & Fire PTY LTD and its distributors. A subpotent product, like one testing at SPF 4, fails to provide the advertised protection, exposing consumers to harmful UV radiation, increasing their risk of sunburn, premature skin aging, and skin cancer. This directly erodes consumer trust and can lead to product liability claims, brand damage, and a significant loss of market share. Conversely, a superpotent product, while potentially offering more protection, indicates a lack of manufacturing control that undermines the product's scientific claims and regulatory approval. For business development executives, this incident highlights the fragility of brand equity built on product efficacy and safety. The financial burden of recalling 44,497 units, including logistics, destruction, and potential legal costs, will be substantial. Furthermore, future product launches or market expansion efforts for the Ultra Violette brand, or any products from Grace & Fire, may face heightened skepticism from retailers and consumers. Supply chain VPs must recognize that such quality deviations necessitate a comprehensive review of their contract manufacturing agreements and internal testing protocols to safeguard against similar failures that can devastate a brand's commercial viability and market presence.

Enhanced Regulatory Scrutiny and Potential Escalation for Grace & Fire PTY LTD

While this is a firm-initiated Class II recall, the severity of the quality defect – a critical efficacy failure for an OTC drug distributed nationwide in the USA – positions Grace & Fire PTY LTD for enhanced regulatory scrutiny from the FDA. The agency views inconsistent SPF results, especially those leading to subpotent products, as a serious public health concern. Regulatory affairs heads should anticipate that this event will likely trigger an FDA inspection of Grace & Fire's manufacturing facility in Cremorne, Australia. During such an inspection, the FDA will meticulously evaluate the company's quality management system, manufacturing processes, and testing methodologies to identify the root cause of the SPF variability. Failure to adequately address these issues and implement robust corrective and preventive actions (CAPAs) could escalate the situation. This could manifest as an FDA Warning Letter, detailing specific violations of Good Manufacturing Practices (GMPs), or even an Import Alert, which would effectively block future shipments of products from the Australian facility into the US market. Procurement directors sourcing from international manufacturers must understand that even voluntary recalls can have long-lasting regulatory consequences, impacting supply continuity and requiring significant resources to regain compliance and market access. Proactive engagement with the FDA and transparent remediation efforts will be critical for Grace & Fire to mitigate further regulatory action.

Mitigating Supply Chain Risk: Lessons from the Ultra Violette Recall

The Ultra Violette SPF 50 recall serves as a critical case study for global chemical and life sciences industry leaders, particularly those involved in procurement and supply chain management of OTC products. To mitigate similar risks, procurement directors must move beyond basic supplier qualification to implement continuous monitoring and performance evaluation. This includes demanding comprehensive batch testing data, conducting regular audits of contract manufacturing organizations (CMOs), and considering independent third-party testing for critical quality attributes like SPF. Robust quality agreements are essential, clearly defining acceptable ranges for active ingredients and finished product efficacy, along with clear protocols for deviation management and recall procedures. For supply chain VPs, diversifying the supplier base for key products or ingredients, where feasible, can reduce reliance on a single point of failure. Furthermore, investing in advanced analytical capabilities for incoming raw materials and outgoing finished products can provide an early warning system for potential quality issues. Business development executives should integrate quality performance metrics into their strategic planning, recognizing that a strong quality record is a competitive advantage. This event reinforces that a proactive, multi-layered approach to quality control, extending from raw material sourcing to finished product distribution, is indispensable for safeguarding consumer health, brand reputation, and uninterrupted market access.

ChemLifeIntel analysis · Catherine Morrow. Compiled from primary and reported sources.
CHEMLIFEINTEL TERMINAL

Go deeper than the brief

The Terminal adds the full entity graph behind this story — downstream buyer-exposure mapping, alternative-supplier shortlists, 5-year compliance footprints and live supply-chain risk scores. Built for procurement, regulatory and business-development teams.

TERMINAL ACCESS
Request Terminal Access

Tell us where to send your access details — covering 1,200+ pharmaceutical and chemical companies across the global value chain.

Covering 1,200+ pharmaceutical and chemical companies across the global value chain
CONNECTED COVERAGE

Related Intelligence

REGULATORY INTELLIGENCE
3d ago

CDSCO Enacts Sweeping Regulatory Changes Across India's Pharma and Medical Device Sectors

India's CDSCO has issued numerous critical regulatory updates, impacting drug formulations, medical devices, and animal health. These changes, including product restrictions, revised fees, and new import rules, necessitate immediate review by procurement, regulatory affairs, and supply chain leaders to maintain compliance and mitigate operational risks across the Indian market.

REGULATORY INTELLIGENCE
3d ago

ANSM Fines Novo Nordisk and Eli Lilly for GLP-1 Obesity Campaign Breaches, Novo Nordisk Explores Legal Challenge

France's ANSM has fined Novo Nordisk and Eli Lilly for obesity campaign breaches related to GLP-1 analogue misuse. This action underscores escalating regulatory scrutiny on high-demand drug marketing. Novo Nordisk is considering a legal challenge, signaling potential prolonged legal and reputational impacts for major pharmaceutical players in the European market.

REGULATORY INTELLIGENCE
4d ago

FDA Faces Pressure to Restrict Livestock Antibiotic Use: Major Commercial Implications for Chemical and Life Sciences

Over 60 organizations have petitioned the FDA to revoke approvals for antibiotic use in livestock for disease prevention and growth promotion. This action, driven by concerns over antibiotic resistance and its human health toll, signals potential significant regulatory shifts. Procurement, supply chain, and regulatory affairs leaders must prepare for market disruption and new compliance requirements.

REGULATORY INTELLIGENCE
4d ago

Germany Abandons Branded Pharmaceutical Price Reduction Plan Amid Industry Opposition

Germany has reversed its decision to implement a variable pricing structure aimed at reducing branded pharmaceutical costs, following significant criticism from drug manufacturers. This move signals a crucial win for pharmaceutical companies, preserving current revenue models and mitigating potential market access challenges in one of Europe's largest economies. Procurement and regulatory teams should reassess their German market strategies.

REGULATORY INTELLIGENCE
4d ago

Health Canada's Drug Product Database: A Critical Resource for Market Intelligence and Regulatory Compliance

Health Canada's Drug Product Database (DPD), last updated March 1, 2019, offers vital intelligence for market access and regulatory compliance. This comprehensive online tool allows stakeholders to query drug identification numbers (DINs), ATC codes, and company data. For procurement, regulatory, and business development executives, the DPD is indispensable for strategic planning and risk management within the Canadian pharmaceutical landscape.

REGULATORY INTELLIGENCE
4d ago

CDSCO Authorizes Oseltamivir Outlets: Clarifying India's Supply Channels for H1N1 Antivirals

India's CDSCO has published a list of authorized outlets for oseltamivir formulation, critical for H1N1 swine flu. This action clarifies legitimate supply channels for this Schedule X drug, signaling intensified regulatory oversight in India's pharmaceutical sector. Procurement and supply chain leaders must ensure compliance with these defined distribution networks to mitigate risks and maintain market access.

REGULATORY INTELLIGENCE
5d ago

Express Scripts, PCMA Challenge Tennessee's FAIR Rx Act: PBM Vertical Integration Under Threat

Express Scripts and the PCMA are challenging Tennessee's FAIR Rx Act, a law prohibiting PBMs from owning pharmacies and restricting mail-order services. This follows CVS Caremark's similar lawsuit. If upheld, the law, effective 2028, threatens to close PBM-affiliated pharmacies, disrupt national drug supply chains, and impede patient access, impacting hundreds of thousands. This legal battle signals escalating state-level pressure on PBM business models.

REGULATORY INTELLIGENCE
6d ago

SonoThera Secures $125M Series B Funding: No FDA Import Alert Information Available

The provided source text details SonoThera's successful $125 million Series B funding round, backed by major pharma entities. Crucially, the source contains no information regarding any FDA Import Alert, regulatory action, facility issues, or product detentions, making an analysis of such an event impossible based on the given data.

REGULATORY INTELLIGENCE
6d ago

FDA Class II Recall: Essential Wellness Pharma's Progesterone Injection Fails Sterility Assurance

Kalman Health & Wellness, Inc. dba Essential Wellness Pharma initiated a Class II recall for its Progesterone 100 mg/mL in Corn Oil Injection due to a critical lack of sterility assurance. This 2015 nationwide recall, terminated in 2017, stemmed from poor sterile production practices at its Peoria, IL facility. For procurement and regulatory leaders, this highlights the severe risks associated with compounded sterile preparations and underscores the imperative for rigorous supplier qualification and ongoing oversight in this sector.

REGULATORY INTELLIGENCE
6d ago

CDSCO Intensifies Regulatory Scrutiny: Implications for India's Pharma and MedTech Supply Chains

CDSCO's recent flurry of alerts, including drug theft, falsified medicines, and product recalls, signals heightened regulatory vigilance across India's pharmaceutical and medical device sectors. This demands robust supply chain security, stringent quality controls, and agile regulatory compliance from global and domestic players. Procurement, regulatory, and supply chain leaders must proactively adapt to mitigate risks and ensure market access.

REGULATORY INTELLIGENCE
6d ago

FDA Hearing Puts Amgen's Tavneos Market Future at Risk Amid Independent Data Review

Amgen faces a critical FDA hearing for its rare disease treatment, Tavneos, following an independent data review. This event could lead to market removal, demanding immediate risk assessment for procurement, supply chain, and regulatory teams. It underscores the FDA's intensified scrutiny on post-market data integrity and product efficacy.

REGULATORY INTELLIGENCE
6d ago

Takeda's TYK2 Inhibitor Victory Reshapes Plaque Psoriasis Market Dynamics

Takeda has secured a significant competitive advantage in the TYK2 inhibitor landscape, outperforming Bristol Myers Squibb’s Sotyktu. This victory positions Takeda strongly for its anticipated plaque psoriasis launch next year, signaling a material shift in market share and procurement strategies for dermatology portfolios. Decision-makers must reassess existing supply agreements and future market entrants.

ENTITY HUBS

Entities in this Brief

GRACE & FIRE PTY LTD
company hub
Open company hub
Ultra Violette Mini SPF Mates kit
molecule hub
Open molecule hub